287 References 51. Corzani R, Luzzi L, Spina D, et al. The prognostic significance of proliferative indices in surgically resected IIIA-N2 Non-small cell lung cancer after induction chemotherapy. J Cardiovasc Surg (Torino). 2014;58(5):763-769. doi:10.23736/S0021-9509.16.08232-X 52. Wen S, Zhou W, Li C ming, et al. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: A meta-analysis of published studies involving 32 studies. BMC Cancer. 2015;15(1). doi:10.1186/s12885-015-1524-2 53. Li LT, Jiang G, Chen Q, Zheng JN. Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 2015;11(3):1566-1572. doi:10.3892/mmr.2014.2914 54. Uramoto H, Tanaka F. Prediction of recurrence after complete resection in patients with NSCLC. Anticancer Res. 2012;32(9):3953-3960. 55. Gennen K, Käsmann L, Taugner J, et al. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2020;15(1). doi:10.1186/ s13014-019-1453-3 56. Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7-14. doi:10.1016/j.ejca.2015.11.020 57. Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma. 2018;65(1):140-146. doi:10.4149/neo_2018_170206N77 58. Yoneda K, Kuwata T, Kanayama M, et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019;121(6):490-496. doi:10.1038/s41416-019-0541-3 59. Fujimoto D, Uehara K, Sato Y, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017;7(1):11373. doi:10.1038/s41598-017-11949-9 60. van den Ende T, van den Boorn HG, Hoonhout NM, et al. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochim Biophys Acta - Rev Cancer. 2020;1874(1). doi:10.1016/j.bbcan.2020.188386 61. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England). 2016;387(10027):1540-1550. doi:10.1016/S01406736(15)01281-7 62. Chen Q, Fu Y-Y, Yue Q-N, et al. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected nonsmall cell lung cancer. Int J Clin Exp Pathol. 2019;12(3):774-786. http://www.ncbi.nlm. nih.gov/pubmed/31933885%0Ahttp://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=PMC6945142 63. Vos CG, Hartemink KJ, Blaauwgeers JLG, et al. Trimodality therapy for superior sulcus tumours: Evolution and evaluation of a treatment protocol. Eur J Surg Oncol. 2013;39(2):197203. doi:10.1016/j.ejso.2012.09.002 64. Formenti SC, Rudqvist N, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845-1851. doi:10.1038/s41591-018-0232-2. Radiotherapy 65. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 Immunohistochemistry Comparability Study in RealLife Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13(9):13021311. doi:10.1016/j.jtho.2018.05.013 66. van Seijen M, Brcic L, Gonzales AN, et al. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch. 2019;475(2):191-199. doi:10.1007/s00428-019-02595-9 A
RkJQdWJsaXNoZXIy MTk4NDMw